Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
August 31, 2023 08:30 ET
|
Biomea Fusion, Inc.
Industry veteran and prominent diabetes clinical development expert to oversee Biomea’s progressing clinical development of novel covalent menin inhibitor BMF-219 in type 2 and type 1 diabetesSteve...
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
July 31, 2023 16:01 ET
|
Biomea Fusion, Inc.
Reported additional positive clinical data at ADA 83rd Scientific Sessions from the first two cohorts of patients with type 2 diabetes from ongoing Phase I/II study (COVALENT-111) evaluating BMF-219...
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
July 24, 2023 09:00 ET
|
Biomea Fusion, Inc.
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4Dose Level 4...
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment
June 23, 2023 21:54 ET
|
Biomea Fusion, Inc.
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing...
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
June 20, 2023 16:30 ET
|
Biomea Fusion, Inc.
New clinical data from COVALENT-111 will be unveiled during a late-breaking poster presentation at ADA’s Scientific SessionsBMF-219, an orally delivered novel covalent menin inhibitor, is designed to...
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
May 02, 2023 16:01 ET
|
Biomea Fusion, Inc.
Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin...
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
May 01, 2023 08:30 ET
|
Biomea Fusion, Inc.
BMF-500, a novel 3rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and developed by Biomea’s FUSION™ System, to advance to the...
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
April 19, 2023 08:30 ET
|
Biomea Fusion, Inc.
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific SessionsBiomea to hold an investor and KOL event during the Scientific Sessions ...
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
April 13, 2023 16:30 ET
|
Biomea Fusion, Inc.
Abstract 473 highlights the dose dependent reduction of menin target genes in ex vivo chronic lymphocytic leukemia (CLL) patient samples treated with BMF-219, an investigational covalent inhibitor....
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
April 13, 2023 09:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and...